Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: PDT/Pharmacia & Upjohn

Executive Summary

PDT/Pharmacia & Upjohn: Companies expand collaboration for the light activated therapy SnET2 (tin ethyl etiopurpurin) to ophthalmology uses. The original collaboration, dating from July 1995, covers development of SnET2 for oncology, urology and dermatology uses. PDT is testing the product in Phase I/II trials for advanced age-related macular degeneration...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel